Veterinarians and researchers are increasingly studying medicinal mushrooms as a complementary approach to support dogs with cancer, holistic experts say.

Proponents point to centuries of mushroom use in traditional medicine and several modern academic investigations that aim to define how fungal compounds might help canine patients, particularly as an adjunct to established therapies. Dr. Rob Silver, a DVM, MS and a holistic veterinarian and medicinal mushroom expert, said the body of research is growing but still small. Common species used include turkey tail, known for its immune-supporting properties and benefits in treating certain cancers, as well as reducing inflammation in the urinary and digestive tracts. Top 5 Medicinal Mushrooms For Dogs are among those commonly referenced.

“We have a few studies, not nearly enough, that show some level of efficacy for the types of cancer that were studied,” Dr. Silver said, underscoring the cautious optimism among clinicians who recommend these products alongside conventional care. Medicinal mushrooms are gaining traction not only in veterinary practice but also in human healthcare, where they are recognized for similar benefits, including immune support and anti-inflammatory effects. Medicinal Mushrooms: Harnessing Nature’s Healing Power provides insights into this comparison.

Dr. Silver described the range of species being used in canine supplements, noting they overlap with prized edible mushrooms. “Many of the mushrooms that are used for medicinal purposes are among some of the most prized edible species such as shiitake, button, cremini, portobello, and oyster, maitake, Lion’s Mane, and cordyceps,” he said. However, dog owners are cautioned to source these mushrooms from reputable suppliers and never to experiment with wild mushrooms, as they can be toxic. Medicinal Mushrooms for Dogs: Uses, Side Effects, and Alternatives outlines important precautions for dog owners.

Among the fungi singled out for canine applications, turkey tail is cited for its comparatively substantial evidence base and reported immune‑supporting effects. Independent academic teams have examined specific mushroom-derived compounds as part of that broader inquiry; institutions such as the University of Pennsylvania and Claremont Graduate University are among those that have conducted related research; the National Institutes of Health has supported or referenced mushroom and PSP research in broader oncology contexts but is not specifically cited in the AKC article as conducting canine trials.

Researchers and clinicians emphasize that medicinal mushrooms are typically considered as complements rather than replacements for standard cancer therapies. “What it did show is that chemo is still stronger than mushrooms, but when you combine mushrooms with chemo, you will get a better response,” Dr. Silver said, describing findings that inform how veterinarians discuss options with owners weighing treatment courses. This nuanced understanding is crucial in ensuring owners feel supported in navigating treatment decisions.

Veterinarians who advise owners on mushroom supplementation note two practical points: formulations vary, and scientific study of specific products in canine patients remains limited. The American Kennel Club has published guidance on medicinal mushroom use for dogs, reviewing species and reported effects in the veterinary context; that overview is one of several resources veterinarians and owners consult as interest grows. Dr. Silver stresses the importance of veterinary supervision when incorporating these supplements, as not all mushrooms are safe or effective for dogs.

Beyond cancer, some individual studies of other mushroom species have reported physiological changes in dogs, such as increased activity of antioxidative enzymes after supplementation with certain preparations. Some academic institutions have contributed research on medicinal functions of mushrooms and their bioactive compounds, reflecting a broader effort to map their potential biological roles.

For owners and clinicians deciding on whether to incorporate mushrooms into a treatment plan, Dr. Silver highlighted a pragmatic assessment. “These factors can help the [owner] decide if treatment is going to provide a better outcome than no treatment,” he said, pointing to quality-of-life considerations that factor into veterinary recommendations. This approach ensures that all treatment avenues are explored while remaining mindful of the dog’s well-being.

As institutions continue trials and comparative work, the research community is also pursuing larger clinical studies of mushroom-derived compounds. Researchers have conducted larger studies on PSP (a polysaccharopeptide derived from turkey tail mushrooms) in cancer, and there is interest in applying such compounds to canine hemangiosarcoma, but specific larger PSP trials in dogs conducted by the National Institutes of Health are not clearly documented in publicly available sources.

For now, clinicians say medicinal mushrooms occupy a complementary role: rooted in historical use and supported by a smattering of modern studies, but still awaiting more extensive, controlled trials to define indications, dosing and long‑term outcomes for canine patients.

Source

Original reporting: view the original article.